NaturMedicinsk klinik - Lafontaine ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  0.0% 18.5% 9.7% 11.3% 16.0%  
Credit score (0-100)  0 7 24 20 12  
Credit rating  N/A B BB BB BB  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12

Net sales  0 0 0 0 0  
Gross profit  0.0 321 263 267 393  
EBITDA  0.0 138 19.3 -12.3 70.2  
EBIT  0.0 97.6 -20.9 -29.9 57.4  
Pre-tax profit (PTP)  0.0 96.9 -22.6 -30.0 57.6  
Net earnings  0.0 72.2 -22.6 -30.0 57.6  
Pre-tax profit without non-rec. items  0.0 96.9 -22.6 -30.0 57.6  

 
See the entire income statement

Balance sheet (kDKK) 
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12

Tangible assets total  0.0 67.8 27.6 10.0 196  
Shareholders equity total  0.0 112 89.6 59.6 117  
Interest-bearing liabilities  0.0 81.3 82.4 136 192  
Balance sheet total (assets)  0.0 259 192 214 325  

Net Debt  0.0 2.3 -7.3 48.4 91.0  
 
See the entire balance sheet

Volume 
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  0.0 321 263 267 393  
Gross profit growth  0.0% 0.0% -18.1% 1.5% 47.2%  
Employees  0 1 1 1 1  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  0 259 192 214 325  
Balance sheet change%  0.0% 0.0% -25.8% 11.4% 51.7%  
Added value  0.0 137.8 19.3 10.4 70.2  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 28 -80 -35 173  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  0.0 1.0 -1.0 -2.0 1.0  

Profitability 
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  0.0% 30.4% -8.0% -11.2% 14.6%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  0.0% 37.7% -9.3% -14.7% 21.4%  
ROI %  0.0% 50.4% -11.4% -16.3% 22.8%  
ROE %  0.0% 64.4% -22.4% -40.2% 65.1%  

Solidity 
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Equity ratio %  0.0% 43.3% 46.6% 27.9% 36.1%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  0.0% 1.6% -37.6% -393.5% 129.6%  
Gearing %  0.0% 72.5% 91.9% 227.6% 163.9%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 1.7% 2.0% 0.2% 0.0%  

Liquidity 
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Quick Ratio  0.0 1.3 1.6 1.3 0.6  
Current Ratio  0.0 1.3 1.6 1.3 0.6  
Cash and cash equivalent  0.0 79.1 89.6 87.2 101.2  

Capital use efficiency 
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  0.0 44.5 62.1 49.6 -79.0  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 138 19 10 70  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 138 19 -12 70  
EBIT / employee  0 98 -21 -30 57  
Net earnings / employee  0 72 -23 -30 58